TY - JOUR
T1 - Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity
AU - Schmitz, Kathryn H.
AU - Neuhouser, Marian L.
AU - Agurs-Collins, Tanya
AU - Zanetti, Krista A.
AU - Cadmus-Bertram, Lisa
AU - Dean, Lorraine T.
AU - Drake, Bettina F.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (U54-CA155850 at University of Pennsylvania [KHS, LTD]; U01CA116850 at the Fred Hutchinson Cancer Research Center [MLN]; 1U54CA155435 at University of California at San Diego [LC-B]; and U54 CA155496 at Washington University [BFD]).
PY - 2013/9/18
Y1 - 2013/9/18
N2 - Evidence that obesity is associated with cancer incidence and mortality is compelling. By contrast, the role of obesity in cancer survival is less well understood. There is inconsistent support for the role of obesity in breast cancer survival, and evidence for other tumor sites is scant. The variability in findings may be due in part to comorbidities associated with obesity itself rather than with cancer, but it is also possible that obesity creates a physiological setting that meaningfully alters cancer treatment efficacy. In addition, the effects of obesity at diagnosis may be distinct from the effects of weight change after diagnosis. Obesity and related comorbid conditions may also increase risk for common adverse treatment effects, including breast cancer-related lymphedema, fatigue, poor health-related quality of life, and worse functional health. Racial and ethnic groups with worse cancer survival outcomes are also the groups for whom obesity and related comorbidities are more prevalent, but findings from the few studies that have addressed these complexities are inconsistent. We outline a broad theoretical framework for future research to clarify the specifics of the biological-social-environmental feedback loop for the combined and independent contributions of race, comorbid conditions, and obesity on cancer survival and adverse treatment effects. If upstream issues related to comorbidities, race, and ethnicity partly explain the purported link between obesity and cancer survival outcomes, these factors should be among those on which interventions are focused to reduce the burden of cancer.
AB - Evidence that obesity is associated with cancer incidence and mortality is compelling. By contrast, the role of obesity in cancer survival is less well understood. There is inconsistent support for the role of obesity in breast cancer survival, and evidence for other tumor sites is scant. The variability in findings may be due in part to comorbidities associated with obesity itself rather than with cancer, but it is also possible that obesity creates a physiological setting that meaningfully alters cancer treatment efficacy. In addition, the effects of obesity at diagnosis may be distinct from the effects of weight change after diagnosis. Obesity and related comorbid conditions may also increase risk for common adverse treatment effects, including breast cancer-related lymphedema, fatigue, poor health-related quality of life, and worse functional health. Racial and ethnic groups with worse cancer survival outcomes are also the groups for whom obesity and related comorbidities are more prevalent, but findings from the few studies that have addressed these complexities are inconsistent. We outline a broad theoretical framework for future research to clarify the specifics of the biological-social-environmental feedback loop for the combined and independent contributions of race, comorbid conditions, and obesity on cancer survival and adverse treatment effects. If upstream issues related to comorbidities, race, and ethnicity partly explain the purported link between obesity and cancer survival outcomes, these factors should be among those on which interventions are focused to reduce the burden of cancer.
UR - http://www.scopus.com/inward/record.url?scp=84886916146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886916146&partnerID=8YFLogxK
U2 - 10.1093/jnci/djt223
DO - 10.1093/jnci/djt223
M3 - Review article
C2 - 23990667
AN - SCOPUS:84886916146
SN - 0027-8874
VL - 105
SP - 1344
EP - 1354
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 18
ER -